// App-Quantinova.ai

Su1025 : COST-EFFECTIVENESS OF INFLIXIMA-S BIOSIMILAR CT-P13 COMPARED TO INNOVATOR INFLIXIMAB FOR THE MANAGEMENT OF Crohn's DISEASE

Researchers

Presenter

  • Christopher Ma

Principal Investigators

  • Christopher McCabe

  • Richard N. Fedorak

  • Brendan P. Halloran

Medical Centers

  • University of Calgary, Calgary, AB, Canada

  • University of Alberta Hospital, Edmonton, Alberta, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab Biosimilar

  • Infliximab

Outcome

  • Unknown

Study Design

  • observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved